

NAVIDEA BIOPHARMACEUTICALS, INC.

Form 8-K

October 11, 2012

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported) October 10, 2012

NAVIDEA BIOPHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware                      001-35076    31-1080091  
(State or other jurisdiction (Commission (IRS Employer  
of incorporation)              File Number) Identification No.)

425 Metro Place North, Suite 450, Dublin, Ohio 43017  
(Address of principal executive offices)              (Zip Code)

Registrant's telephone number, including area code (614) 793-7500

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ..              Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ..              Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

“ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events.**

On October 10, 2012, Navidea Biopharmaceuticals, Inc. (the “Company”) issued a press release announcing that it had posted an update on the status of the Lymphoseek® (technetium Tc 99m tilmanocept) Injection (“Lymphoseek”) new drug application (“NDA”) review on the Company’s website. The update stated that, as part of its continuing effort to secure regulatory NDA approval for Lymphoseek, a Type A meeting with the United States Food and Drug Administration (“FDA”) had been scheduled to advance the Company’s planned response to the FDA regarding deficiencies in current Good Manufacturing Practice (“cGMP”) identified during inspections at third-party manufacturing facilities.

The Company has now successfully completed the Type A meeting with the FDA and has received clarifying guidance from the Agency in regard to the cGMP issues noted in the FDA’s Complete Response Letter (“CRL”) received on September 10, 2012, and the requirements for the Company’s response to the CRL for the Lymphoseek NDA. The meeting confirmed that the scope of the Company’s resubmission will be focused on the previously noted cGMP manufacturing deficiencies observed at third-party manufacturing facilities. The meeting further affirmed the requirements that the Company must address in its resubmission.

A copy of the complete text of the Company’s October 10, 2012, press release, and the referenced update on the status of the Lymphoseek NDA, are attached as Exhibit 99.1 and 99.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.

Statements contained or incorporated by reference in this Current Report on Form 8-K which relate to other than strictly historical facts, such as statements about the Company’s plans and strategies, expectations for future financial performance, new and existing products and technologies, anticipated clinical and regulatory pathways and markets for the Company’s products, are forward-looking statements. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” and similar expressions identify forward-looking statements that speak only as of the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited to, the Company’s continuing operating losses, uncertainty of market acceptance of its products, reliance on third party manufacturers, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and distribution channels, competition, limited marketing and manufacturing experience, risks of development of new products, regulatory risks and other risks detailed in the Company’s most recent Annual Report on Form 10-K and other Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

Exhibit

Number Exhibit Description

- |      |                                                                                                                                                                |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 99.1 | Navidea Biopharmaceuticals, Inc. press release, dated October 10, 2012, entitled "Navidea Biopharmaceuticals Posts Lymphoseek® NDA Update to Company Website." |
| 99.2 | Navidea Biopharmaceuticals, Inc. update, posted October 10, 2012, entitled "Navidea Provides Lymphoseek® NDA Update Statement."                                |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Navidea Biopharmaceuticals, Inc.

Date: October 10, 2012 By: /s/ Brent L. Larson  
Brent L. Larson, Senior Vice President and  
Chief Financial Officer